JP2013515073A5 - - Google Patents

Download PDF

Info

Publication number
JP2013515073A5
JP2013515073A5 JP2012546129A JP2012546129A JP2013515073A5 JP 2013515073 A5 JP2013515073 A5 JP 2013515073A5 JP 2012546129 A JP2012546129 A JP 2012546129A JP 2012546129 A JP2012546129 A JP 2012546129A JP 2013515073 A5 JP2013515073 A5 JP 2013515073A5
Authority
JP
Japan
Prior art keywords
compound
hydrogen
gluc
stereoisomer
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012546129A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013515073A (ja
JP5760008B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/061420 external-priority patent/WO2011079091A1/en
Publication of JP2013515073A publication Critical patent/JP2013515073A/ja
Publication of JP2013515073A5 publication Critical patent/JP2013515073A5/ja
Application granted granted Critical
Publication of JP5760008B2 publication Critical patent/JP5760008B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012546129A 2009-12-22 2010-12-21 (メチルスルホニル)エチルベンゼンイソインドリン誘導体及びその治療的使用 Expired - Fee Related JP5760008B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28935609P 2009-12-22 2009-12-22
US61/289,356 2009-12-22
PCT/US2010/061420 WO2011079091A1 (en) 2009-12-22 2010-12-21 (methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses

Publications (3)

Publication Number Publication Date
JP2013515073A JP2013515073A (ja) 2013-05-02
JP2013515073A5 true JP2013515073A5 (https=) 2014-02-13
JP5760008B2 JP5760008B2 (ja) 2015-08-05

Family

ID=43528318

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012546129A Expired - Fee Related JP5760008B2 (ja) 2009-12-22 2010-12-21 (メチルスルホニル)エチルベンゼンイソインドリン誘導体及びその治療的使用

Country Status (18)

Country Link
US (1) US8716252B2 (https=)
EP (1) EP2516395A1 (https=)
JP (1) JP5760008B2 (https=)
KR (1) KR20120113219A (https=)
CN (1) CN102770412A (https=)
AU (1) AU2010333767A1 (https=)
BR (1) BR112012015129A2 (https=)
CA (1) CA2783616A1 (https=)
CL (1) CL2012001671A1 (https=)
CO (1) CO6640204A2 (https=)
CR (1) CR20120335A (https=)
EC (1) ECSP12011987A (https=)
MX (1) MX2012007217A (https=)
PH (1) PH12012501237A1 (https=)
RU (1) RU2012131164A (https=)
SG (1) SG181891A1 (https=)
WO (1) WO2011079091A1 (https=)
ZA (1) ZA201203944B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012236655B2 (en) 2011-03-28 2016-09-22 Deuterx, Llc, 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
CA2935495C (en) 2013-01-14 2021-04-20 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
EP2968334A4 (en) 2013-03-14 2016-08-03 Deuterx Llc 3- (SUBSTITIERTES-4-OXO-quinazolin-3 (4H) -yl) -3-deutero-PIPERIDINE-2,6-DIONE DERIVATIVES
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
WO2017157873A1 (en) 2016-03-17 2017-09-21 F. Hoffmann-La Roche Ag 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar
US20190008837A1 (en) * 2016-12-15 2019-01-10 University Of Utah Research Foundation Ophthalmic compositions and associated methods
KR102277626B1 (ko) * 2018-08-16 2021-07-15 한국화학연구원 이소인돌린-1온 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
MX2022003490A (es) 2019-09-27 2022-04-25 Takeda Pharmaceuticals Co Derivados de 2-isoindol-1,3,4-oxadiazol utiles como inhibidores de la histona desacetilasa 6 (hdac6).

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
WO1995003009A1 (en) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
WO1995003807A1 (en) 1993-07-27 1995-02-09 The University Of Sydney Treatment of age-related macular degeneration
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
IT1274549B (it) 1995-05-23 1997-07-17 Indena Spa Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
US5728844A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
US5800819A (en) 1996-01-25 1998-09-01 National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
NZ333903A (en) 1996-07-24 2000-02-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1oxoisoindolines and method of reducing TNF-alpha levels in a mammal
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US6015803A (en) 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
US6225348B1 (en) 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
US6001368A (en) 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
CN1511420A (zh) 2001-11-09 2004-07-07 ���µ�����ҵ��ʽ���� 运动图像编码方法和装置
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en) 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US20050100529A1 (en) 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
KR20120039065A (ko) 2003-12-02 2012-04-24 셀진 코포레이션 혈색소병증 및 빈혈의 치료 및 관리를 위한 방법및 조성물
US20050143344A1 (en) 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
BRPI0509019A (pt) 2004-03-22 2007-08-07 Celgene Corp métodos para tratar, prevenir ou controlar um distúrbio ou doença de pele, para tratar, prevenir ou controlar ceratose senil e para tratar ou controlar ceratose, composição farmacêutica, forma de dosagem unitária individual, e, kit
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
US20050239842A1 (en) 2004-04-23 2005-10-27 Zeldis Jerome B Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
CN101098694A (zh) 2004-11-12 2008-01-02 细胞基因公司 使用免疫调节化合物治疗和控制寄生性疾病的方法和组合物
JP2008520731A (ja) 2004-11-23 2008-06-19 セルジーン・コーポレーション 中枢神経系傷害を治療及び管理するための、免疫調節性化合物を使用した方法及び組成物
BRPI0518793A2 (pt) 2004-12-01 2008-12-09 Celgene Corp mÉtodos para tratar, controlar ou prevenir uma doenÇa ou distérbio de imunodeficiÊncia, e para melhorar a resposta imune a um imunogene, e, composiÇço farmacÊutica
SI1928492T1 (sl) 2005-09-01 2011-09-30 Celgene Corp Imunoloĺ ka uporaba imunomodulatornih spojin za cepivo in protiinfekcijsko bolezensko terapijo
JP5410285B2 (ja) * 2006-10-12 2014-02-05 アステックス、セラピューティックス、リミテッド 医薬化合物

Similar Documents

Publication Publication Date Title
JP2013515073A5 (https=)
JP2013519675A5 (https=)
JP2010502627A5 (https=)
JP2014501789A5 (https=)
JP2018021046A5 (https=)
RU2017127135A (ru) Терапевтическое средство против рака желчных протоков
JP2015501783A5 (https=)
CL2013002593A1 (es) Forma cristalina a1 de la sal clorhidrato del compuesto 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una enfermedad o trastorno tal como cancer, angiogenesis, dolor, trastorno pulmonar y un trastorno del snc.
JP2015521167A5 (https=)
JP2016528301A5 (https=)
JP6238460B2 (ja) 脂質異常症治療剤
JP2009506117A5 (https=)
JP2016540749A5 (https=)
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
BR112015021888A2 (pt) inibidores de dna-ik
MX2015003728A (es) Combinacion de regorafenib y acido acetilsalicilico para el tratamiento del cancer.
JP2018507914A5 (https=)
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
JP2016500063A5 (https=)
JP2013522326A5 (https=)
JP2012504560A5 (https=)
NI201600048A (es) Formulaciones de (s)- 3- (4-((4-(morfolinometil) bencil)oxi)-1-oxoisoindolin-2-il) piperidin-2, 6-diona
JP2013542261A5 (https=)
JP2014509653A5 (https=)
JP2018538273A5 (https=)